000			02655na a2200433 4500
999			_c1685 _d1685
003			PC1685
005			20210625062757.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAyala Díaz, Rosa María _91206 _eHematología y Hemoterapia
100			_aFernández Redondo, Elena _92459 _eHematología y Hemoterapia
100			_aLahuerta Palacios, Juan José _9388 _eHematología y Hemoterapia
100			_aMartínez López, Joaquín _9389 _eHematología y Hemoterapia
100			_aMartínez Sánchez, María Pilar _9732 _eHematología y Hemoterapia
100			_aMontalbán Pallarés, María Ángeles _91465 _eHematología y Hemoterapia
245	0	0	_aClinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. _h[artículo]
260			_bBritish Journal of Haematology, _c2013
300			_a163(5):581-9.
500			_aFormato Vancouver: Martínez López J, Fernández Redondo E, García Sanz R, Montalbán MA, Martínez Sánchez P, Pavia B, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013;163(5):581-9.
501			_aPMID: 24117042
504			_aContiene 39 referencias
520			_aMinimal residual disease monitoring is becoming increasingly important in multiple myeloma (MM), but multiparameter flow cytometry (MFC) and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) techniques are not routinely available. This study investigated the prognostic influence of achieving molecular response assessed by fluorescent-PCR (F-PCR) in 130 newly diagnosed MM patients from Grupo Espanol Multidisciplinar de Melanoma (GEM)2000/GEM05 trials (NCT00560053, NCT00443235, NCT00464217) who achieved almost very good partial response after induction therapy. As a reference, we used the results observed with simultaneous MFC. F-PCR at diagnosis was performed on DNA using three different multiplex PCRs: IGH D-J, IGK V-J and KDE rearrangements. The applicability of F-PCR was 91<bold>5</bold>%. After induction therapy, 64 patients achieved molecular response and 66 non-molecular response; median progression-free survival (PFS) was 61 versus 36months, respectively (P=0<bold>001</bold>). Median overall survival (OS) was not reached (NR) in molecular response patients (5-year survival: 75%) versus 66months in the non-molecular response group (P=0<bold>03</bold>). The corresponding PFS and OS values for patients with immunophenotypic versus non-immunophenotypic response were
710			_9297 _aServicio de Hematología y Hemoterapia
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1685.pdf _ySolicitar documento
942			_n0 _2ddc _cART